US2017027945A1PendingUtilityA1
Novel Compounds
Est. expiryDec 8, 2028(~2.4 yrs left)· nominal 20-yr term from priority
A61P 9/04A61P 3/10A61P 9/14A61P 9/00A61P 7/02A61P 9/10A61P 3/06A61P 3/04A61P 3/00A61P 13/12A61P 1/14C07D 473/06A61K 31/133A61K 31/522C07D 473/04
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a tris salt of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione of Formula (A): corresponding manufacture processes, pharmaceutical formulations containing and uses of the aforementioned compound in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for treating stroke in a human subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound which is crystalline 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione tris(hydroxymethyl)aminomethane anhydrate (Formula (IA)):
having an XRPD pattern as shown in FIG. 2 .
2 . The method according to claim 1 wherein the crystalline form of the compound is characterised by an XRPD pattern comprising the following peaks:
Position
d-spacing
(±0.2° 2-theta)
((Å))
10.1
8.7
10.5
8.4
12.2
7.3
13.0
6.8
13.5
6.5
17.3
5.1
17.5
5.1
17.9
5.0
18.3
4.8
19.2
4.6
19.8
4.5
20.2
4.4
20.6
4.3
20.9
4.2
21.7
4.1
22.1
4.0
23.3
3.8
23.9
3.7
24.6
3.6
26.3
3.4
27.1
3.3
27.9
3.2
28.2
3.2
28.6
3.1
29.6
3.0
3 . The method according to claim 1 wherein the crystalline form of the compound is characterised by a melting endotherm with an onset melting temperature of 212±2° C. in a DSC thermogram.
4 . The method according to claim 1 wherein the crystalline form of the compound is characterised by the following absorption peaks in an ATR-IR spectrum of the solid product: 3370, 3041, 2946, 2858, 1680, 1656, 1528, 1266, 1243, 1078, 1068, 1049±1 cm-1.
5 . The method according to claim 1 wherein the crystalline form of the compound is characterised in that it has an ATR infra red spectrum that is substantially as shown in FIG. 6 .Join the waitlist — get patent alerts
Track US2017027945A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.